BioAI, a biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, has announced a strategic partnership with Arbele, a biopharmaceutical company dedicated to developing novel immunotherapeutic platforms for gastrointestinal cancers.
The collaboration aims to leverage BioAI's PredictX platform to develop AI-based models using Arbele's clinical trial data, with a focus on colorectal cancer (CRC) biomarker screening. The goal is to create a companion diagnostic test for Arbele's drug assets, enhancing patient selection through advanced AI technology.
"By joining forces with Arbele, we are excited to apply our novel AI platform and expertise to accelerate the development of innovative treatment options for gastrointestinal cancers," said Thomas Colarusso, CEO of BioAI. "This partnership underscores our commitment to revolutionizing personalized medicine through cutting-edge machine learning."
Arbele's CEO and Founder, Dr John Luk, commented: "BioAI's machine learning capabilities offer a transformative approach to biomarker identification and patient stratification. This collaboration is a critical step in improving outcomes for patients with high mortality cancers."
The initial phase of the partnership will focus on developing a prototype machine learning classifier model for quantifying CDH17 expression patterns in CRC samples, using a combination of H&E (haematoxylin and eosin) and IHC (immunohistochemistry) stained images. This initiative aims to standardise and improve the pathologic assessment of treatment response biomarkers to facilitate more effective patient selection for Arbele's specific therapeutic programs. Both companies expect that this collaboration will pave the way for future advances in precision medicine, ultimately benefiting patients with gastrointestinal cancers.